by Peter Ciszewski | Aug 10, 2021
Thanos Zomas, MD, from Takeda Oncology, discusses the 5-year long-term data analysis of the ECHELON-2 study, which was recently presented at EHA 2021. The ECHELON-2 study was a double-blind, randomized, multicenter, phase 3 clinical trial that finished in 2018....
by Peter Ciszewski | Aug 9, 2021
Brenton Mar, MD, PhD, Senior Medical Director at Blueprint Medicines, gives an overview of systemic mastocytosis and advanced systemic mastocytosis. As Dr. Mar explains, systemic mastocytosis is a rare, hematologic disorder most often caused by a mutation in...
by Peter Ciszewski | Aug 6, 2021
Gary Joseph Lelli, MD, of the Department of Ophthalmology at Weill Cornell Medicine, discusses the difference between thyroid eye disease (TED) and Graves’ disease by highlighting the signs and symptoms of TED. TED is a rare autoimmune disease causing...
by Peter Ciszewski | Aug 5, 2021
Omar Sinno, MD, Medical Lead of Rare Disease at UCB, describes the company’s dedication to developing treatment for rare diseases like myasthenia gravis. Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal...
by Peter Ciszewski | Aug 4, 2021
Roman Groisberg, MD, Medical Oncologist and Director of the Sarcoma Program at Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, discusses treatment options available for different sarcomas. Sarcomas are rare cancers that develop in the bones and soft...
